science
Eli Lilly Supplied Experimental Obesity Drug to One Patient via FDA Compassionate-Use Program
Stat reported that Eli Lilly supplied its experimental drug retatrutide to a single patient through the FDA’s compassionate-use pathway in April. The request involved a 79-year-old man and drew attention from senior health officials. Retatrutide has produced substantial weight loss in clinical studies.
benzinga.comAudio version
Tap play to generate a narrated version.
Developing·Limited corroboration so far. This page will refresh as more sources emerge.
Eli Lilly supplied its experimental obesity drug retatrutide to one patient through the FDA’s compassionate-use program, Stat reported. The request occurred in April and concerned a 79-year-old man, according to three sources familiar with the matter. The FDA’s compassionate-use pathway permits access to unapproved treatments for patients facing serious or immediately life-threatening conditions.
Retatrutide, developed by Eli Lilly, produced weight-loss results comparable to bariatric surgery in clinical testing. The request drew the interest of top health officials, the sources said. They requested anonymity citing fear of reprisals and indicated the recipient held connections that elevated the case.
Stat published the report on June 23, 2026.
Transparency
How sources framed this
Single source — no framing comparison available.
CorroborationModerate · 1 source
